| Dr Theresa Zaleski, DO | |
|
296 Saint Charles Way, York, PA 17402-4648 | |
| (717) 812-5050 | |
| (717) 741-2427 |
| Full Name | Dr Theresa Zaleski |
|---|---|
| Gender | Female |
| Speciality | Micrographic Dermatologic Surgery (mds) |
| Experience | 13 Years |
| Location | 296 Saint Charles Way, York, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134401524 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| York Hospital | York, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
News Archive
Only a quarter of U.S. primary care physicians surveyed are doing a thorough job of helping patients achieve and maintain a healthy weight, finds a study in the American Journal of Health Promotion.
A team from the Universitat Politècnica de València has developed a new mobile application that facilitates the continuous monitoring of the quality of life of cancer patients.
New research from Columbia University Medical Center may explain why people who are able to easily and accurately recall historical dates or long-ago events, may have a harder time with word recall or remembering the day's current events.
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
› Verified 1 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
Only a quarter of U.S. primary care physicians surveyed are doing a thorough job of helping patients achieve and maintain a healthy weight, finds a study in the American Journal of Health Promotion.
A team from the Universitat Politècnica de València has developed a new mobile application that facilitates the continuous monitoring of the quality of life of cancer patients.
New research from Columbia University Medical Center may explain why people who are able to easily and accurately recall historical dates or long-ago events, may have a harder time with word recall or remembering the day's current events.
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Theresa Zaleski, DO 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 812-5050 | Dr Theresa Zaleski, DO 296 Saint Charles Way, York, PA 17402-4648 Ph: (717) 812-5050 |
News Archive
Only a quarter of U.S. primary care physicians surveyed are doing a thorough job of helping patients achieve and maintain a healthy weight, finds a study in the American Journal of Health Promotion.
A team from the Universitat Politècnica de València has developed a new mobile application that facilitates the continuous monitoring of the quality of life of cancer patients.
New research from Columbia University Medical Center may explain why people who are able to easily and accurately recall historical dates or long-ago events, may have a harder time with word recall or remembering the day's current events.
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer.
› Verified 1 days ago
Dr. Heather Leanne Salvaggio, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 205 Saint Charles Way, York, PA 17402 Phone: 717-741-4666 Fax: 717-741-0538 | |
Samantha Haraszti, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 296 Saint Charles Way, York, PA 17402 Phone: 717-812-5050 | |
Stacy Klepeiss, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 205 Saint Charles Way, York, PA 17402 Phone: 717-741-4666 Fax: 717-741-9649 | |
Karen Marie Waltz, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1934 Security Drive, York, PA 17402 Phone: 717-741-3761 Fax: 717-741-9495 | |
Dr. Natalie Ivana Bene, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 400 Pine Grove Cmns, York, PA 17403 Phone: 717-755-4422 Fax: 717-755-2390 | |
Mr. Ira J Berman, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 205 Saint Charles Way, York, PA 17402 Phone: 717-741-4666 Fax: 717-741-9649 |